AstraZeneca Pharma India Receives ESG Rating of 64 from Crisil ESG Ratings
AstraZeneca Pharma India Limited has been assigned an ESG rating of 64 by Crisil ESG Ratings & Analytics Limited. The rating is based on publicly available information for fiscal year 2026. Crisil ESG Ratings independently prepared the report.
The ESG rating is based on publicly available information and was not solicited by the company. Therefore, its immediate impact on the company's stock or operations is likely to be low.
The announcement is a factual disclosure of an ESG rating assigned by a third party based on publicly available information. It does not contain any performance improvements or declines, hence it is neutral.
AstraZeneca Pharma India Limited has received an Environmental, Social, and Governance (ESG) rating of 64 from Crisil ESG Ratings & Analytics Limited.
This rating is based on publicly available information pertaining to the fiscal year 2026. It is important to note that the company did not engage Crisil ESG Ratings for this assessment; the report was independently prepared by Crisil ESG Ratings using publicly available data.
The disclosure was made on September 2, 2026.
A plain-language summary of a public exchange filing by AstraZeneca Pharma India Limited. Read the original for the full detail.